Research and development of new methods for manufacturing large numbers of immune cells to inhibit cancer recurrence

Copyright © iCell Bioscience Inc, Shanghai 2018-2019

Recently, a research report published in the international magazine Cell Reports, scientists from Mount Sinai Hospital first developed a new method to create a large number of immune cells to help inhibit cancer recurrence.

Researchers have developed new methods for large-scale production of dendritic cells in the laboratory, helping to create highly refined cancer vaccines to effectively prevent disease recurrence in cancer patients. Dendritic cells are rare in the body, if not expensive With highly sophisticated methods, researchers can hardly isolate dendritic cells from patients to make cancer vaccines.

Dendritic cells can act as a "sentinel" to alert the body's immune system to a variety of diseases, and the ability to make a variety of dendritic cells can help scientists study the key role that dendritic cells play in the body's immune system. This research finds it important because dendritic cells are not limited to a type of cancer that attacks many types of cancer and has very limited side effects.

The ability to produce large numbers of different types of dendritic cells in vitro is critical to speeding up researchers' understanding of the biological properties of dendritic cells, while also helping to effectively use dendritic cells to treat human disease in the clinic; researchers in this study The special system developed has certain transformation application value, including in vitro drug research and vaccine test for a variety of different dendritic cells.

The researchers analyzed the key role of the Notch signaling pathway, which plays a key role in many organisms such as fruit flies and even humans, and is also critical for the production of specific types of dendritic cells (cDC1), which is manufactured. The best dendritic cells for cancer vaccines.

The researchers point out that some of the currently being tested cancer therapies have certain drawbacks because they interfere with the Notch signaling pathway, thereby inhibiting the function of cDC1, which may negatively affect the body's ability to kill cancer cells.

This research is a starting point for researchers to further study different types of dendritic cells and other immune cells. It has a wide range of values and significance, which not only enhances the development of anti-cancer immunotherapy, but also effectively inhibits patients' organs. Transplant rejection (directly related to the body's immune system).

Later researchers will also delve into the research, and they hope to use these dendritic cells to develop effective vaccines for treating or preventing multiple types of cancer.